Peptide | 125I-CRFKi | 125I-SauvagineKi | 125I-ASTKi | 125I-aSVG Ki |
---|---|---|---|---|
nM | ||||
hCRF | 41.6 ± 4.03-a | 57.3 ± 5.23-b | 130 ± 253-c | 304 ± 63-d 3-e |
oCRF | 115 ± 133-f | 239 ± 103-g | 930 ± 1023-g 3-h | 1165 ± 1303-g 3-h |
rUCN | 0.59 ± 0.10 | 0.34 ± 0.08 | 2.75 ± 0.15 | 1.81 ± 0.27 |
hUCN | 0.64 ± 0.11 | 0.28 ± 0.05 | 0.72 ± 0.04 | 0.98 ± 0.20 |
Urotensin I | 1.18 ± 0.19 | 1.88 ± 0.20 | 34.3 ± 2.93-h | 55.2 ± 4.33-e |
Sauvagine | 0.66 ± 0.09 | 0.47 ± 0.04 | 25.8 ± 3.13-h | 20.0 ± 2.23-h |
α-hel CRF | 10.4 ± 1.8 | 10.9 ± 1.7 | 12.3 ± 0.8 | 8.16 ± 0.64 |
AST | 1.63 ± 0.17 | 1.52 ± 0.30 | 1.30 ± 0.06 | 1.50 ± 0.04 |
aSVG | N.A. | 0.27 ± 0.01 | 1.75 ± 0.21 | 0.83 ± 0.03 |
The data are means ± S.E. from at least three different binding experiments performed in triplicate.
N.A., not analyzed.
Statistically significant differences:
↵3-a p < 0.0001 vs. rUCN, hUCN, urotensin I, sauvagine, α-hel CRF, and AST;
↵3-b p < 0.0001 vs. rUCN, hUCN, urotensin I, SVG, α-hel CRF, AST, and aSVG;
↵3-c p < 0.01 vs. rUCN, hUCN, AST, and aSVG;
↵3-d p < 0.0005 vs. rUCN, hUCN, AST, and aSVG;
↵3-e p < 0.0005 vs. 125I-CRF, 125I-sauvagine, and125I-AST;
↵3-f p < 0.0001 vs. hCRF, rUCN, hUCN, urotensin I, sauvagine, α-hel CRF, and AST;
↵3-g p < 0.0001 vs. hCRF, rUCN, hUCN, urotensin I, sauvagine, α-hel CRF, AST, and aSVG;
↵3-h p < 0.0001 vs.125I-CRF and 125I-sauvagine.